Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.91 |
| ▸ | MTOR | P42345 | 1/20 | 0.91 |
| ▸ | ADK | P55263 | 1/20 | 0.91 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | VCP | P55072 | 2/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL7409338 | 0.98 | NISCH (0.95) | NISCHMTORADKALDH1A1KDM4E | |
| 2-Phenylimidazole SCHEMBL9719773 | 0.96 | NISCH (1.00) | NISCHMTORADKALDH1A1KDM4E | |
| 2-Phenylimidazole SCHEMBL8901 | 0.96 | NISCH (1.00) | NISCHMTORADKALDH1A1KDM4E | |
| 2-Phenylimidazole SCHEMBL8898735 | 0.93 | NISCH (0.95) | NISCHMTORADKALDH1A1KDM4E | |
| 2-Phenylimidazole SCHEMBL1881537 | 0.93 | NISCH (0.95) | NISCHMTORADKALDH1A1KDM4E | |
| 2-Phenylimidazole SCHEMBL31511436 | 0.93 | NISCH (0.95) | NISCHMTORADKALDH1A1KDM4E | |
| 2-Phenylimidazole SCHEMBL5796856 | 0.93 | NISCH (0.95) | NISCHMTORADKALDH1A1KDM4E | |
| 2-Phenylimidazole SCHEMBL1954238 | 0.93 | NISCH (0.95) | NISCHMTORADKALDH1A1KDM4E | |
| 2-Phenylimidazole SCHEMBL11072040 | 0.93 | NISCH (0.95) | NISCHMTORADKALDH1A1KDM4E | |
| 2-Phenylimidazole SCHEMBL28283863 | 0.93 | NISCH (0.95) | NISCHMTORADKALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114891230-B | Functionalized MOF material, preparation method and application thereof as solid phase extraction adsorbent | 山东省分析测试中心 | 2023-06-13 | — | — | CN | claimed |
| CN-114891230-A | Functionalized MOF material, preparation method and application of functionalized MOF material as solid-phase extraction adsorbent | 山东省分析测试中心 | 2022-08-12 | — | — | CN | claimed |
| CN-117482548-A | Production device and process for synthesizing aldehyde through hydroformylation of olefin | 万华化学集团股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117362675-A | Preparation of cobalt-based metal organic framework material and application of cobalt-based metal organic framework material in resolution of cis-trans isomer of 1, 4-cyclohexanedicarboxylic acid | 北京工业大学 | 2024-01-09 | — | — | CN | disclosed |
| CN-114891230-B | Functionalized MOF material, preparation method and application thereof as solid phase extraction adsorbent | 山东省分析测试中心 | 2023-06-13 | — | — | CN | disclosed |
| CN-114891230-A | Functionalized MOF material, preparation method and application of functionalized MOF material as solid-phase extraction adsorbent | 山东省分析测试中心 | 2022-08-12 | — | — | CN | disclosed |
| CN-111689946-A | Carbazole aromatic ring thermal activation delayed fluorescent material and organic electroluminescent device thereof | 深圳大学 | 2020-09-22 | — | — | CN | disclosed |
| US-9169282-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-9169282-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-20110284799-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
| US-20110284799-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
| WO-2010086089-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2010-08-05 | — | — | WO | disclosed |
| CN-101267809-A | Sugar coatings and methods therefor | WYETH CORP (US) | 2008-09-17 | — | — | CN | disclosed |
| EP-1861387-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006080821-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2006-08-03 | — | — | WO | disclosed |
| EP-1257551-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS PARP INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001057038-A9 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS PARP INHIBITORS | BASF AG (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001057038-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS PARP INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-08-09 | — | — | WO | disclosed |
| CN-1265033-A | Certain diarylimidaozle derivatives, new class of NPY speific ligands | NEUROGEN CORP (US) | 2000-08-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110284799-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | NISCH 1434/4885MTOR 4584/4885ADK 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.